Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $287 Price Target

Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?

Johnson & Johnson is expected to report Q3 2026 earnings of $2.90 per share (up 3.6% YoY) and revenues of $25.37 billion (up 5.8% YoY) on October 13. However, the company's Earnings ESP is -0.01% with a Zacks Rank #3, making it difficult to predict an earnings beat. While JNJ has beaten consensus estimates in all four of the last quarters, recent analyst revisions have turned slightly bearish, suggesting the stock may not be a compelling earnings-beat candidate.

9 Of 11 Sectors Rise In Tuesday Trading As Defensives Lead

Nine of 11 sectors are higher in Tuesday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Utilities well ahead of the next group.

RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $290